个人化医疗的全球市场规模:各产品，各终端用户，各地区，范围及预测

个人化医疗市场规模及预测

2024年个人化医疗市场规模为1,302.3亿美元，预估2024年至2031年复合年增长率为10.67%，预估至2031年将达2725.9亿美元。个人化医疗（也称为精准医疗）是一种根据个人特定基因组成和其他个人特征量身定制预防、诊断和治疗等医疗保健决策的医疗方法。这种治疗利用基因测试和生物标记的数据来优化治疗，并确保患者获得最有效的药物和最少的副作用。

个人化医疗应用包括药物基因组学（根据个体的基因图谱确定最佳药物和剂量）、针对特定癌症的针对独特分子标靶的标靶治疗以及针对特定疾病的预防措施。

此外，个人化医疗利用先进技术和从人类基因组计划等项目获得的数据，透过提供更精确和专业的治疗来改善患者的治疗结果。

个人化医疗的全球市场动态

塑造个人化医疗市场的主要市场动态

主要市场驱动因子

癌症和遗传疾病的盛行率不断增加：

癌症和遗传疾病的日益普及正在推动对个人化医疗技术的需求。根据世界卫生组织 (WHO) 的数据，癌症是全球头号死因，2020 年将导致约 1,000 万人死亡。国际癌症研究机构（IARC）预测，到2040年，全球癌症患者数将达到2,840万，比2020年增加47%。癌症负担的增加正在推动标靶治疗和个人化治疗方法的发展。

基因体定序技术的进展：

基因定序技术的快速进步使个人化医疗变得更加容易获得和负担得起。根据美国国家人类基因组研究所的数据，人类基因组定序的成本已从 2001 年的约 1 亿美元大幅下降到 2021 年的不到 1,000 美元。这种显着的成本降低增加了基因检测在临床实践中的使用，并实现了个人化的治疗选择。

增加对精准医疗计画的投资：

政府和企业正在增加对精准医学研究和实施的投资。例如，美国国立卫生研究院 (NIH) 制定了“我们所有人研究与开发计划”，该计划收集了超过 100 万美国人的数据，旨在加速研究并改善健康结果。截至 2023 年 9 月，该计划已招募超过 746,000 人，超过 482,000 人提交了生物样本进行基因组分析。这项大规模的努力反映了人们对扩大个人化医疗方法日益增长的兴趣。

主要问题

医疗保健差距：

个人化医疗是基于主要从欧洲人群获得的基因组数据，导致不同种族和民族群体的治疗效果有偏差。这种低估导致演算法无法可靠地预测来自不同背景的患者的反应，从而扩大了现有的医疗保健差距。

监理监督：

随着个人化医疗技术的进步，监管机构需要製定新标准，以评估其与传统治疗相比的安全性和有效性。这包括制定将遗传和生物标记数据整合到临床实践中的指南。由于缺乏评估此类创新的临床疗效和成本效益的既定程序，阻碍了它们的批准和广泛接受，限制了该领域的进展。

主要趋势：

基因组诊断与标靶治疗的整合：

随着医院越来越多地利用这些尖端技术，他们现在能够根据患者独特的 DNA 图谱提供个人化的治疗计划。这一趋势将提高医疗干预的精确度，并实现更有效的疾病管理，包括癌症，可以根据特定的肿瘤特征定製药物，最终改善患者的治疗结果和满意度。

增加对数位健康解决方案的投资：

随着远距医疗、行动健康应用程式和穿戴式装置的出现，可以持续监控患者的健康数据并即时更改治疗方案。这些技术透过提供有关患者健康状况和治疗反应的资讯、促进更具协作性的医疗保健方法以及提高对个人化治疗方案的依从性来增强患者的能力。

个人化营养与健康：

对个人化营养和健康的日益重视已成为个人化医疗市场的重要组成部分。随着消费者的健康意识越来越强，对解决特定遗传特征和健康问题的个人化营养方案和补充剂的需求不断增长。这一趋势反映出人们对饮食如何影响健康和疾病管理有了更全面的了解，从而在解决特定健康问题的同时促进整体健康。

目录

第1章 简介

• 市场定义
• 市场区隔
• 调查手法

第2章 摘要整理

• 主要调查结果
• 市场概要
• 市场亮点

第3章 市场概要

• 市场规模与成长的可能性
• 市场趋势
• 推动市场要素
• 阻碍市场要素
• 市场机会
• 波特的五力分析

第4章 个人化医疗市场:各产品类型

• 个人化医疗诊断药
• 个人化医疗治疗药

第5章 个人化医疗市场:各用途

• 肿瘤学
• 神经学
• 循环系统
• 其他的用途

第6章 个人化医疗市场:各终端用户

• 医院及诊所
• 研究机关及研究所
• 製药·生物科技企业
• 患者

第7章 地区分析

• 北美
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 南美
• 巴西
• 阿根廷
• 智利
• 中东·非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第8章 市场动态

• 推动市场要素
• 阻碍市场要素
• 市场机会
• COVID-19对市场的影响

第9章 竞争情形

• 主要企业
• 市场占有率分析

第10章 企业简介

• Roche
• Illumina
• Novartis
• Amgen
• Merck & Co., Inc.
• Thermo Fisher Scientific
• QIAGEN
• Myriad Genetics
• Exact Sciences Corporation
• IQVIA
• Syneos Health

第11章 市场展望和机会

• 新兴技术
• 今后的市场趋势
• 投资机会

第12章 附录

• 简称清单
• 出处和参考文献

Personalized Medicine Market Size and Forecast

Personalized Medicine Market size was valued at USD 130.23 Billion in 2024 and is projected to reach USD 272.59 Billion by 2031 , growing at a CAGR of 10.67% from 2024 to 2031. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare decisions-such as prevention, diagnosis, and treatment-to an individual's specific genetic composition and other personal traits. This practice uses data from genetic testing and biomarkers to optimize therapeutic actions, ensuring that patients receive the most effective medicines with the fewest negative effects.

Personalized medicine applications include pharmacogenomics, which helps determine the best medications and dosages for individuals based on their genetic profiles; targeted therapies for specific cancers that focus on unique molecular targets; and preventive measures informed by genetic predisposition to certain diseases.

Furthermore, personalized medicine uses advanced technologies and data from programs such as the Human Genome Project to improve patient outcomes by providing more precise and specialized treatment

Global Personalized Medicine Market Dynamics

The key market dynamics that are shaping the personalized medicine market include:

Key Market Drivers

Increasing Prevalence of Cancer and Genetic Disorders:

The increased prevalence of cancer and genetic disorders is pushing the need for personalized medicine techniques. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that the worldwide cancer burden will reach 28.4 million cases in 2040, up 47% from 2020. The increasing cancer burden is driving the development of targeted treatments and personalized treatment approaches.

Advancements in Genomic Sequencing Technologies:

Rapid advancements in genetic sequencing technology are making customized medicine more accessible and inexpensive. According to the National Human Genome Research Institute, the cost of sequencing a human genome has decreased drastically, from approximately USD 100 Million in 2001 to less than $1,000 in 2021. This large cost reduction has resulted in increased usage of genetic testing in clinical settings, allowing for personalized treatment options.

Growing Investment in Precision Medicine Initiatives:

Governments and corporate entities are increasing their investments in precision medicine research and implementation. For example, the National Institutes of Health (NIH) in the United States developed the All of Us Research Program, which intends to collect data from one million or more Americans to speed up research and improve health outcomes. As of September 2023, the initiative had registered over 746,000 people, with over 482,000 submitting biosamples for genomic analysis. This large-scale endeavor reflects the growing interest in expanding personalized medicine approaches.

Key Challenges:

Healthcare Disparities:

Personalized medicine is based primarily on genomic data from European populations, which leads to therapeutic efficacy biases for varied racial and ethnic groups. This underrepresentation leads to algorithms that do not reliably anticipate reactions from patients from various backgrounds, increasing existing healthcare disparities.

Regulatory Oversight:

The development of new standards by regulatory bodies is necessary as personalized medicine technologies progress to assess their safety and effectiveness in comparison to conventional treatments. This includes developing guidelines for integrating genetic and biomarker data into clinical practice. The absence of established procedures for evaluating the clinical and cost-effectiveness of these innovations hampers their approval and widespread acceptance, limiting progress in this field.

Key Trends:

Integration of Genomic Diagnostics and Targeted Therapies:

Hospitals can now offer individualized treatment plans based on patient's unique DNA profiles as they use these cutting-edge technologies more frequently. This trend increases the accuracy of medical interventions, allowing for more effective disease management, such as cancer, where medications can be tailored to specific tumor characteristics, ultimately increasing patient outcomes and satisfaction.

Growing Investment in Digital Health Solutions:

The advent of telemedicine, mobile health apps, and wearable devices has enabled continuous monitoring of patient health data, allowing for real-time alterations to treatment programs. These technologies empower patients by providing them with information on their health and treatment responses, promoting a more collaborative approach to healthcare and increasing adherence to individualized treatment regimens.

Personalized Nutrition and Wellness:

There is a growing emphasis on tailored nutrition and wellness, which is emerging as a crucial area of the personalized medicine market. As customers become more health-conscious, there is a growing need for personalized dietary regimens and supplements that address specific genetic profiles and health concerns. This trend reflects a more comprehensive understanding of how diet affects health and illness management, resulting in creative solutions that promote overall well-being while addressing specific health concerns.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Personalized Medicine Market Regional Analysis

Here is a more detailed regional analysis of the personalized medicine market:

Asia Pacific:

According to Verified Market Research, the Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The increased frequency of cancer and genetic illnesses in the Asia Pacific region is driving demand for personalized medical strategies. According to the International Agency for Research on Cancer (IARC), Asia accounted for over half of all new cancer cases worldwide in 2020, with an estimated 8.9 million new cases. According to the IARC, by 2040, this number will climb to around 14.5 million new cases per year in Asia. This rising cancer burden is driving investments in genetic research and personalized treatment strategies throughout the region.

Furthermore, the Asia Pacific region's population is rapidly growing and aging, creating demand for personalized healthcare solutions. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's population is predicted to grow from 4.3 billion in 2020 to 4.7 billion in 2050. Also, the population aged 65 and up is expected to more than quadruple, from 395 million in 2020 to 956 million by 2050. This generational transition is increasing the demand for more tailored and effective medical treatments, hence boosting the personalized medicine market.

North America:

North America is estimated to dominate the personalized medicine market during the forecast period. North America, particularly the United States, has a significant burden of chronic diseases that can be addressed using personalized medicine approaches. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. In 2019, around 37.3 million Americans (11.3% of the total population) had diabetes. The rising frequency of chronic diseases creates a desire for more targeted and effective therapies provided by personalized medicine.

Furthermore, North America has a well-developed healthcare infrastructure that easily accepts new technology, helping the adoption of personalized medicine. According to the US Food and Drug Administration (FDA), the number of approved personalized medicines has increased significantly. In 2022, personalized medicines accounted for 25% of all new drug approvals, up from 5% in 2005. This trend reflects the region's ability to translate research into practical applications, hence boosting the expansion of the personalized medicine market.

Global Personalized Medicine Market: Segmentation Analysis

The Personalized Medicine Market is segmented based on Product, End-User, and Geography.

Personalized Medicine Market, By Product

• Personalized Medicine Diagnostics
• Personalized Medicine Therapeutics
• Personalized Medical Care
• Personalized Nutrition & Wellness

Based on Product, the market is segmented into Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition & Wellness. The personalized medicine diagnostics segment is estimated to dominate the personalized medicine market. This dominance is primarily driven by the growing demand for improved diagnostic tools capable of detecting genetic variants and biomarkers associated with a variety of disorders, including cancer. The rising frequency of chronic diseases needs more precise diagnostic procedures, resulting in increased investment in genetic testing and direct-to-consumer diagnostics.

Personalized Medicine Market, By End-User

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others

Based on End-User, the Personalized Medicine Market is divided into Hospitals, Diagnostic Centers, Research & Academic Institutes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to hospitals' crucial role as key providers of personalized healthcare services, which incorporate genomic diagnostics and tailored medicines into patient care. Their specialized facilities and skills enable them to efficiently implement innovative treatment approaches, thereby driving the expansion of personalized medicine and determining its future clinical practice.

Personalized Medicine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Personalized Medicine Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the market during the forecasted period due to the region's superior healthcare infrastructure, significant R&D investments, and high rates of chronic diseases such as cancer and diabetes. Furthermore, the substantial presence of top biotech and pharmaceutical businesses promotes innovation and acceptance of customized medicine solutions, firmly establishing North America as a market leader.

Key Players

• The "Personalized Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Roche, Illumina, Novartis, Amgen, Merck & Co., Inc., Thermo Fisher Scientific, QIAGEN, Myriad Genetics, Exact Sciences Corporation, IQVIA, and Syneos Health.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Personalized Medicine Market Recent Developments
• In September 2023, Agilent Technologies and Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) signed a Memorandum of Understanding (MOU) to advance gene and cell therapy over the next three years.
• In July 2023, Pillar Biosciences and Illumina announced a strategic alliance to commercialize Pillar's range of oncology assays globally. Completing the agreement will provide unprecedented Next-Generation Sequencing (NGS) technologies, increasing patient access to individualized cancer treatment options.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Personalized Medicine Market, By Product Type

• Individualized Medical Care Diagnostics
• Individualized Medical Care Therapeutics

5. Personalized Medicine Market, By Application

• Oncology
• Neurology
• Cardiology
• Additional Uses

6. Personalized Medicine Market, By End User

• Hospitals and Clinics
• Research Institutions and Laboratories
• Pharmaceutical and Biotechnology Companies
• Patients

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Roche
• Illumina
• Novartis
• Amgen
• Merck & Co., Inc.
• Thermo Fisher Scientific
• QIAGEN
• Myriad Genetics
• Exact Sciences Corporation
• IQVIA
• Syneos Health

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References